September 22, 2025Idorsia Ltd. (SIX: IDIA) announces that Simcere Pharmaceuticals Group Ltd (2096.HK, “Simcere”) has launched ...
Most recently, the Phase III pivotal clinical trial results of Fazamorexant, a first-class innovative anti-insomnia drug ...
MedPage Today on MSN
Novel Drug Fails to Outperform Common Treatment in Depression and Insomnia
An investigational drug did not significantly improve outcomes versus quetiapine extended release (Seroquel XR) as an ...
Switzerland-based Idorsia announced that its licensee Simcere Pharmaceuticals has launched Quviviq (daridorexant), a dual ...
Harmony Biosciences Holdings faces setbacks after a failed trial and sNDA rejection. Click here to find out why HRMY is a ...
Allschwil, Switzerland - September 22, 2025Idorsia Ltd. (SIX: IDIA) announces that Simcere Pharmaceuticals Group Ltd (2096.HK, "Simcere") has launched QUVIVIQ® (daridorexant) in China. QUVIVIQ, Idorsi ...
Analysts' ratings for Harmony Biosciences Hldgs (NASDAQ: HRMY) over the last quarter vary from bullish to bearish, as provided by 6 analysts. Summarizing their recent assessments, the table below ...
Phase 2 ASCEND trial of solengepras, a novel, non-dopaminergic GPR6 inhibitor, showed evidence of potential benefit in ...
In reality, people with insomnia may reach for their phones because they can’t sleep—not the other way around. Lying in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback